• Maia Biotechnology reported progress in its pivotal Phase 3 THIO-104 trial of ateganosine as third-line therapy for advanced NSCLC.
• Enrollment reached 65 randomized patients, supporting the company’s plan to exceed 100 by year-end.
• Results were already presented as an interim assessment from the Phase 2 THIO-101 study.
• The update indicated disease control in heavily pretreated patients, outperforming typical third-line chemotherapy outcomes.
• FDA Fast Track status for NSCLC could speed review timelines, supporting a potential earlier regulatory pathway if Phase 3 data hold.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maia Biotechnology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609220847PRIMZONEFULLFEED9830847) on September 22, 2026, and is solely responsible for the information contained therein.